Medicare does cover transcatheter aortic valve replacement (TAVR), classifying it as an inpatient hospital procedure under Part A. Coverage has been in place since 2012, when the Centers for Medicare and Medicaid Services (CMS) issued a national coverage determination for the procedure. But “covered” and “straightforward” are not the same thing. The path from diagnosis to a covered TAVR involves specific eligibility requirements, facility standards, and out-of-pocket costs that vary depending on your particular Medicare plan.
How Medicare Coverage Works for TAVR
TAVR falls under Medicare Part A, which handles inpatient hospital stays. When you’re admitted to a hospital for TAVR, Part A covers the hospital room, nursing care, the valve device itself, and related services during the stay. If you have Original Medicare, you’re responsible for the Part A deductible for that benefit period and any coinsurance that kicks in after a certain number of hospital days. Since most TAVR patients are discharged within a few days, the coinsurance for extended stays rarely applies.
Medicare Advantage plans (Part C) also cover TAVR, but the specifics depend on your plan. Some Advantage plans require prior authorization before the procedure can go forward, which can add steps and time. The cost-sharing structure, including copays and out-of-pocket maximums, differs from plan to plan. If you’re on an Advantage plan, calling the plan directly to ask about TAVR coverage before scheduling is worth the effort.
The physician fees for the cardiologist and any other specialists involved in the procedure are billed separately under Medicare Part B. You’d typically owe 20 percent of the Medicare-approved amount for those services after meeting your Part B deductible, unless you have a Medigap policy that picks up some or all of that share.
Who Qualifies Under Medicare’s Rules
Medicare’s national coverage determination for TAVR requires that a multidisciplinary heart team evaluate you before the procedure is approved. This team typically includes an interventional cardiologist, a cardiac surgeon, and other specialists who assess your anatomy, overall health, and surgical risk. The heart team model is not optional window dressing; it is a formal CMS requirement for coverage. The team reviews your case and collectively decides whether TAVR, traditional open-heart surgery, or medical management is the best fit.
The heart team’s role has evolved as TAVR has expanded to lower-risk patients. Originally approved only for people considered too sick for open-heart surgery, TAVR gained FDA approval for intermediate-risk patients in 2016 and low-risk patients in 2019. That expansion triggered a rapid increase in real-world TAVR use among Medicare beneficiaries. A study using the CMS claims database found that between 2018 and 2020 alone, more than 77,000 Medicare beneficiaries underwent TAVR compared with about 33,000 who had traditional surgical aortic valve replacement.
The heart team combines scientific evidence, cross-specialty expertise, and the patient’s own preferences to arrive at a recommendation.
Facility and Registry Requirements
Not every hospital can bill Medicare for TAVR. CMS requires that the procedure be performed at facilities meeting specific standards, including minimum procedure volumes and participation in a national outcomes registry. The STS/ACC Transcatheter Valve Therapy (TVT) Registry, a joint initiative of the Society of Thoracic Surgeons and the American College of Cardiology, serves as the primary data-collection mechanism. Hospitals performing TAVR must submit detailed patient and outcome data to this registry as a condition of Medicare reimbursement.
This registry requirement serves two purposes. It ensures ongoing quality monitoring at each hospital, and it feeds a national database that researchers and policymakers use to track how well TAVR performs in everyday practice outside of clinical trials. By the end of 2014, the registry had already captured over 26,000 TAVR procedures.
The practical effect of these facility requirements is that TAVR is concentrated at larger hospitals, usually in metropolitan areas. Between 2012 and 2018, 583 hospitals launched new TAVR programs, and nearly all of them, about 98 percent, were in metropolitan areas. Half of those new programs opened in metro areas that already had at least one TAVR-capable hospital nearby.
What You Can Expect to Pay Out of Pocket
Even with Medicare coverage, TAVR involves significant costs that the system absorbs and, to a lesser extent, costs that land on the patient. The total hospital bill for a TAVR procedure has historically run in the range of $50,000 to $65,000, with the implanted valve prosthesis driving much of that expense. For Original Medicare beneficiaries, the Part A inpatient deductible (which changes annually, currently over $1,600 per benefit period) is the primary direct cost, along with Part B coinsurance for physician services.
From Medicare’s perspective, the economics of TAVR have been closely scrutinized. Early data from 2012 showed that Medicare spent about $215 million nationally on roughly 4,000 TAVR patients in the procedure’s first year of clinical use. At that time, Medicare payments for TAVR hospitalizations were slightly lower than for matched surgical valve replacements, but hospitals’ actual costs were higher for TAVR, largely because of the expensive valve device. The gap between what Medicare paid and what the procedure cost left many hospitals with a negative margin on TAVR cases.
That financial picture has shifted. More recent data comparing costs across risk groups shows that index hospitalization costs are now significantly lower for TAVR than for surgical replacement across all risk levels. Among low-risk patients, for instance, TAVR hospitalization costs averaged about $62,000 compared to roughly $69,000 for surgery. Follow-up costs through one year were also lower with TAVR, particularly in low-risk groups, where the difference was several thousand dollars. Those savings come from shorter hospital stays and fewer post-surgical complications.
For you as a patient, the most relevant number is your plan’s cost-sharing structure rather than the total hospital charge. A Medigap supplemental policy can substantially reduce what you owe. If you’re on a Medicare Advantage plan, your out-of-pocket maximum caps your total annual spending, though copays for the hospital stay and specialist visits still apply.
Pre-Procedure Workup and Wait Times
Before TAVR can proceed, you’ll go through a series of diagnostic tests and specialist consultations that Medicare covers under Part B. These typically include cardiac imaging (CT scans of the heart and blood vessels, echocardiograms), blood work, pulmonary function testing, and visits with the heart team members. All of this is standard pre-operative evaluation, and Medicare pays for medically necessary diagnostic services.
What catches many patients off guard is how long this workup takes. Research examining the pre-procedural pathway found that TAVR patients waited roughly 157 days from initial evaluation to the actual procedure, compared with about 98 days for patients going the surgical route. That roughly two-month difference was driven almost entirely by the additional testing and specialist visits required for TAVR. TAVR patients underwent nearly twice as many cardiac specialist visits and imaging procedures as surgical patients, and those extra requirements accounted for about 83 percent of the delay.
That delay is not just an inconvenience. Among Medicare beneficiaries with severe aortic stenosis, waiting longer for TAVR is associated with higher healthcare costs. One study found that patients who waited 12 months for their TAVR incurred about $10,000 more in healthcare spending compared to those who received the procedure promptly, driven by emergency visits, hospitalizations, and worsening symptoms during the wait.
Telemedicine has emerged as one way to shorten the timeline. A study of nearly 500 patients found that those who completed their preoperative evaluation via telemedicine had outcomes comparable to those evaluated in person, with no meaningful differences in 30-day complications, mortality, readmissions, or stroke rates. If your TAVR center offers a telemedicine option for some of the pre-procedure visits, it may help speed things along without compromising safety.
How TAVR Outcomes Have Changed Over Time in Medicare Patients
The track record of TAVR in Medicare beneficiaries has been closely monitored through claims data, giving an unusually clear picture of how the procedure performs in real-world conditions rather than the controlled setting of a clinical trial. An analysis of Medicare patients from 2012 through 2019 found that TAVR was associated with lower mortality than surgical replacement throughout that period, though the size of the advantage shifted over time. The mortality benefit of TAVR over surgery was largest around 2016, then narrowed somewhat as outcomes for both procedures improved. A similar pattern appeared for hospital readmissions.
One clear and consistent advantage of TAVR is recovery time. Year over year throughout the study period, TAVR patients were discharged dramatically faster than surgical patients, and that gap widened over time. By 2019, TAVR patients were leaving the hospital about five times sooner than their surgical counterparts.
The overall volume of aortic valve procedures among Medicare beneficiaries has also climbed. Between 2012 and 2019, total aortic valve replacements per 100,000 beneficiary-years rose from 107 to 156, with virtually all of that growth driven by TAVR. TAVR rates jumped from 19 to 101 per 100,000 beneficiary-years, while surgical rates dropped from 88 to 54. The median age of TAVR patients also decreased during this period, from 84 to 81, reflecting the expansion of TAVR to lower-risk, younger patients.
Special Situations and Coverage Edges
Medicare’s coverage of TAVR is clearest for patients with a standard three-leaflet (tricuspid) aortic valve who have severe aortic stenosis. The evidence base that underpins CMS coverage was built primarily on this population. But a meaningful number of people needing valve replacement have a bicuspid aortic valve, a congenital variation where the valve has two leaflets instead of three. Bicuspid valves present different anatomical challenges, and the question of whether TAVR works as well in these patients is still being sorted out.
Medicare does cover TAVR for bicuspid valve patients in practice, but the outcomes data suggest more caution is warranted. A study using the CMS claims database from 2018 to 2022 found that among bicuspid valve patients, TAVR was associated with lower procedural mortality than surgery but higher rates of permanent pacemaker implantation (about 12 percent versus 2 percent), higher long-term stroke risk, and higher overall mortality over the follow-up period. Even among younger, low-risk bicuspid patients, TAVR was linked to a higher composite rate of stroke, valve reintervention, or death compared to surgery.
A separate Medicare-based study of bicuspid patients found a similar pattern over a three-year follow-up. Mortality was comparable between TAVR and surgery in the first six months, but between six months and three years, TAVR was associated with roughly double the mortality risk. Heart failure readmissions followed the same trajectory: lower with TAVR in the first six months but substantially higher over the longer term.
These findings do not mean Medicare will deny coverage for TAVR in bicuspid patients, but they do mean the heart team evaluation becomes especially important. For younger patients with bicuspid valves who are reasonable surgical candidates, the data increasingly favor surgery for long-term durability.
Cardiac Rehabilitation After TAVR
Medicare covers cardiac rehabilitation for patients who have undergone valve replacement, including TAVR. Cardiac rehab typically involves supervised exercise, education on heart-healthy living, and counseling. Under Medicare Part B, you can receive up to 36 sessions, with the possibility of an additional 36 sessions if your doctor certifies ongoing medical necessity.
Despite being covered, cardiac rehab is significantly underused among TAVR patients. The procedure’s less invasive nature and quick recovery sometimes create the impression that rehab is unnecessary, but the typical TAVR patient is elderly, often deconditioned, and living with multiple chronic conditions. Structured rehabilitation can improve exercise capacity, reduce frailty, and lower the risk of readmission. If your cardiologist does not bring up cardiac rehab after TAVR, it is worth asking about it yourself.
Access Disparities Among Medicare Beneficiaries
Coverage on paper does not always translate into equal access in practice. Research has consistently documented that TAVR utilization varies by race, ethnicity, and socioeconomic status among Medicare beneficiaries. An analysis of the TVT Registry found that among more than 70,000 TAVR patients, over 91 percent were white, while Black patients made up less than 4 percent and Hispanic patients about 3 percent. Those figures represent significant underrepresentation relative to their share of the Medicare population.
The disparities appear to be driven in part by where TAVR programs are located. Within major metropolitan areas that have TAVR-capable hospitals, zip codes with higher proportions of Black and Hispanic residents and greater socioeconomic disadvantage had lower TAVR rates, even after adjusting for age and clinical conditions. Hospitals that established new TAVR programs between 2012 and 2018 tended to be in areas with higher median household incomes and fewer patients dually eligible for Medicare and Medicaid, a marker of poverty. Areas with lower economic distress had higher TAVR rates per 100,000 Medicare beneficiaries.
Whether these gaps reflect differences in the underlying burden of aortic stenosis, differences in referral patterns, barriers to reaching specialized centers, or some combination remains an open question. But the practical implication for patients in underserved communities is clear: having Medicare coverage for TAVR does not guarantee the same ease of access that a beneficiary in an affluent metro area might experience. If you live far from a TAVR center or in a community with fewer cardiovascular specialists, getting a referral and navigating the pre-procedure workup may take more initiative and more time.
The Declining Cost of TAVR and What It Means for Coverage
The economics of TAVR continue to evolve in ways that could shape Medicare policy going forward. The cost of the valve devices themselves has been declining as more manufacturers enter the market and newer-generation devices compete on price. A review of cost-effectiveness data noted that while surgical replacement was historically the more cost-effective option, TAVR has been catching up and in many analyses now compares favorably, particularly as device prices drop and hospital stay lengths shrink.
This trend matters for Medicare because the program’s willingness to cover a procedure is influenced by its cost-effectiveness relative to alternatives. As TAVR becomes less expensive per case, the financial case for broad coverage strengthens. The total volume of TAVR procedures has grown enormously since 2012, and because TAVR patients generally spend fewer days in the hospital and incur lower follow-up costs over the first year, the aggregate savings to Medicare can be substantial even though the upfront device cost remains high. One analysis found that cumulative one-year costs were substantially lower with TAVR than with surgery across all patient risk levels.
For patients, the declining cost trajectory is encouraging but indirect. Your out-of-pocket share is determined by Medicare’s reimbursement rules and your supplemental coverage, not by the hospital’s underlying costs. Still, lower procedure costs tend to reduce financial pressure on hospitals to be selective about which patients they treat, potentially widening access over time.